Jasper Therapeutics, INC 8-K filings

Jasper Therapeutics announced its fiscal year 2023 financial results, highlighted by a $50 million financing and progress in clinical trials for its lead drug candidate, briquilimab.

Jasper Therapeutics has announced the pricing of a $50 million underwritten public offering of common stock to fund its clinical development programs and for general corporate purposes.